vida: extract claims from 2026-05-07-psychopharmacology-institute-q1-2026-glp1-review

- Source: inbox/queue/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md
- Domain: health
- Claims: 2, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-prescribing-competency-gap-creates-structural-safety-risk-through-primary-care-psychiatric-drug-misclassification.md

@@ -16,3 +16,10 @@ related: ["human-in-the-loop-clinical-ai-degrades-to-worse-than-ai-alone", "valu
 # GLP-1 prescribing competency gap creates structural safety risk through primary care psychiatric drug misclassification
 
 GLP-1 receptor agonists engage VTA, nucleus accumbens, insula, and prefrontal cortex to directly regulate reward pathways and reinforcement learning — making them functionally psychiatric drugs. However, they are prescribed primarily by primary care physicians for weight loss without psychiatric monitoring infrastructure. Dr. Sauvé states: 'If our field of psychiatry does not get a hundred percent ahead of how this GLP thing works, then we're going to be left behind.' The competency gap is structural: psychiatrists manage patients on GLP-1s they didn't prescribe, without understanding central mechanisms, dosing nuances, or psychiatric side effects. This creates a supervision gap for drugs that directly modulate dopaminergic reward circuits — the same circuits targeted by psychiatric medications. The gap exists because the drugs are classified and prescribed as metabolic agents despite their primary mechanism involving psychiatric circuitry. This is distinct from the general GLP-1 prescribing competency gap because it specifically concerns the mismatch between psychiatric mechanism and non-psychiatric prescriber training.
+
+
+## Extending Evidence
+
+**Source:** Psychopharmacology Institute Q1 2026 Review
+
+Psychopharmacology Institute Q1 2026 guidance establishes monthly monitoring using validated depression/suicidality tools and psychoeducation for mood lability, appetite changes, and suicidal ideation as the psychiatric-specific monitoring protocol. This protocol is disseminated through CME to psychiatrists but not systematically available to primary care prescribers.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -164,3 +164,10 @@ EVOKE failure in Alzheimer's disease with confirmed pathology defines the bounda
 **Source:** Sa et al. (2026)
 
 Systematic review cites 29% alcohol reduction with dulaglutide and notes 'potential benefits in SUD' as an emerging therapeutic application. Review characterizes this as operating through reward pathway modulation consistent with mesolimbic dopamine mechanism.
+
+
+## Challenging Evidence
+
+**Source:** Psychopharmacology Institute Q1 2026 Review
+
+Psychopharmacology Institute Q1 2026 guidance omits substance use disorder applications entirely, despite JAMA Psychiatry RCT evidence for AUD being available by Q1 2026. This suggests professional society guidance lags clinical evidence by approximately 1 year, creating a gap between published efficacy data and clinical practice recommendations.

domains/health/glp1-schizophrenia-metabolic-screening-uses-5-4-percent-hba1c-threshold-for-preventative-intervention.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: "Psychiatric guidance recommends initiating GLP-1 metabolic screening at HbA1c 5.4% for patients on clozapine or olanzapine, establishing a preventative threshold distinct from standard diabetes screening protocols"
+confidence: experimental
+source: Psychopharmacology Institute Q1 2026 Review, schizophrenia-specific companion article
+created: 2026-05-07
+title: "GLP-1 metabolic screening for schizophrenia patients uses 5.4% HbA1c threshold for early-stage risk targeting, below the 5.7% prediabetes cutoff"
+agent: vida
+sourced_from: health/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md
+scope: functional
+sourcer: Psychopharmacology Institute
+related: ["glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring"]
+---
+
+# GLP-1 metabolic screening for schizophrenia patients uses 5.4% HbA1c threshold for early-stage risk targeting, below the 5.7% prediabetes cutoff
+
+The Psychopharmacology Institute's Q1 2026 guidance establishes a 5.4% HbA1c screening threshold for initiating GLP-1 consideration in schizophrenia patients on clozapine or olanzapine. This threshold is 0.3 percentage points below the standard 5.7% prediabetes cutoff, positioning GLP-1 as a preventative metabolic intervention rather than a treatment for established metabolic dysfunction. The rationale is that antipsychotic-induced weight gain and metabolic syndrome are common and predictable side effects, making early intervention appropriate for patients who cannot easily switch antipsychotic medications. The guidance frames this population as the priority use case: patients on necessary but metabolically harmful antipsychotics who require metabolic protection while remaining on their psychiatric treatment. This represents a distinct clinical protocol from standard diabetes prevention, where intervention typically begins at the prediabetes threshold. The 5.4% cutoff creates a psychiatric-specific metabolic screening protocol that anticipates rather than reacts to metabolic deterioration.

domains/health/psychiatry-addresses-glp1-competency-through-cme-not-formal-guidelines-creating-uneven-distribution.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Professional society guidance for psychiatric GLP-1 use is emerging through continuing medical education platforms rather than formal clinical practice guidelines, leaving primary care prescribers without structured competency pathways
+confidence: experimental
+source: Psychopharmacology Institute Q1 2026 Review
+created: 2026-05-07
+title: Psychiatry addresses GLP-1 prescribing competency through CME infrastructure rather than formal APA guidelines, creating uneven competency distribution across the prescriber population
+agent: vida
+sourced_from: health/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md
+scope: structural
+sourcer: Psychopharmacology Institute
+supports: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access"]
+related: ["glp1-prescribing-competency-gap-creates-structural-safety-risk-through-primary-care-psychiatric-drug-misclassification", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal", "glp1-eating-disorder-screening-protocol-scoff-plus-history-plus-behavioral-assessment-recommended-for-pre-treatment-risk-stratification", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
+---
+
+# Psychiatry addresses GLP-1 prescribing competency through CME infrastructure rather than formal APA guidelines, creating uneven competency distribution across the prescriber population
+
+As of Q1 2026, no formal American Psychiatric Association clinical practice guideline exists for GLP-1 receptor agonist use in psychiatric populations. Instead, the Psychopharmacology Institute — a widely used CME platform for psychiatrists — published structured clinical guidance as part of their quarterly review. This guidance includes specific protocols: HbA1c screening at 5.4% for schizophrenia patients on clozapine/olanzapine (below the 5.7% prediabetes threshold), monthly monitoring using validated depression/suicidality tools, and psychoeducation for patients and caregivers about mood lability and appetite changes. The Institute frames schizophrenia patients on metabolically harmful antipsychotics as the priority population, positioning GLP-1 as a metabolic side effect management tool rather than a primary psychiatric intervention. Notably, the guidance omits substance use disorder applications entirely, despite JAMA Psychiatry RCT evidence being available by Q1 2026. This creates a two-tier competency system: psychiatrists who engage with CME platforms receive structured protocols, while primary care prescribers — who write the majority of psychiatric medications — lack formal guidance. The ~60-hour ABOM certification represents the formal competency pathway, but CME represents the informal, higher-volume channel. The absence of SUD guidance despite available evidence suggests a ~1-year lag between clinical evidence publication and professional society guidance dissemination.

entities/health/psychopharmacology-institute.md

@@ -0,0 +1,24 @@
+# Psychopharmacology Institute
+
+**Type:** Continuing Medical Education (CME) platform  
+**Focus:** Psychiatry and mental health prescribing  
+**Significance:** De facto clinical guidance infrastructure for US psychiatrists in the absence of formal APA clinical practice guidelines
+
+## Overview
+
+The Psychopharmacology Institute is a widely used CME platform for psychiatrists and mental health prescribers in the United States. As of Q1 2026, it functions as the primary channel through which psychiatrists receive structured clinical guidance on emerging psychopharmacology topics, including GLP-1 receptor agonist use in psychiatric populations.
+
+## Role in GLP-1 Psychiatric Guidance
+
+In the absence of formal American Psychiatric Association clinical practice guidelines for GLP-1 use, the Institute's quarterly reviews serve as de facto professional guidance. The Q1 2026 review established specific protocols for GLP-1 use in schizophrenia patients on clozapine or olanzapine, including:
+
+- HbA1c screening threshold of 5.4% (below the 5.7% prediabetes cutoff)
+- Monthly monitoring using validated depression/suicidality tools
+- Psychoeducation protocols for patients and caregivers
+- Priority population framing: metabolic side effect management for patients on necessary antipsychotics
+
+The Institute's guidance represents the informal, high-volume competency pathway for psychiatrists, contrasting with the formal ~60-hour ABOM certification pathway.
+
+## Timeline
+
+- **2026-04-01** — Published Q1 2026 review covering GLP-1 RAs in psychiatric practice, establishing clinical protocols for schizophrenia patients on metabolically harmful antipsychotics

inbox/archive/health/2026-05-07-psychopharmacology-institute-q1-2026-glp1-review.md

@@ -7,10 +7,13 @@ date: 2026-04-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-07
 priority: high
 tags: [glp-1, psychiatry, clinical-guidance, CME, schizophrenia, monitoring, suicidality]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content